Postdoctoral Positions

Part of the mission of the Salk Institute for Biological Studies is to train individuals for careers in scientific research. The expectation is that trainees will study in the many new fields developed by Institute faculty, learn the research techniques they have created, and go on to positions of leadership in other prominent scientific institutions. Postdoctoral training opportunities at the Institute are posted below.

If you are interested in working with a faculty member who does not have a posting below, you should correspond directly with that faculty member.

If you have recently accepted a postdoctoral position at the Institute, please contact Academic Services.

The Salk Institute is an Equal Opportunity Employer.

Recommended browsers using a PC or a Mac: IE 7+, Firefox, Safari on the Mac, Chrome.
      Successful submissions with tablets and smartphones cannot be guaranteed.
All posted positions close at 11:59 PST of the Closes On Date, unless posted as Open Until Filled.
←Return to List
Job #: F496
Posted Date: February 23, 2017
Closes On: Open Until Filled
Job Title: Research Associate/Postdoctoral Scientist - Translational Research (Immunology/Oncology)
Status: Regular Full Time
Benefits Eligible: Yes
Laboratory/Department: Molecular and Cell Biology Laboratory
Laboratory employs the help of a small DNA virus, called adenovirus, to both understand and treat cancer. DNA viruses and tumor cells sabotage such controls to drive their respective pathological propagation, albeit with one small difference: In tumor cells the key cellular players are targeted via mutations, while in infected cells viral proteins achieve the same end. Not surprisingly, many of the cellular targets are the same. Dr. O'Shea's lab is exploiting this overlap to help address three key questions: What are the critical cellular targets and pathways that drive deregulated growth? What is the human growth deregulation program and how do we uncouple it for tumor therapy? Can we manipulate viruses as novel therapeutic agents that trigger the rapid lytic death of tumor cells but leave normal cells unharmed?
Position Description:

The Salk Institute of Biological Studies is seeking an experienced Immunologist/ Oncologist to join a Translational Group with the responsibility of developing a new pipeline of virus-based therapeutics delivering immune modulatory payloads for the treatment of cancer. This is a “hands-on” scientist role focused on translational research that is well suited for postdoctoral scientists potentially interested in a transition to a biotech/industry setting. The successful candidate is expected to have a strong scientific background in immunology/oncology. Major activities will include:

  • Conceive and design new immune-stimulatory therapeutics using novel platform technology
  • Develop and execute in vitro assays to evaluate virus candidates for potency and immune activity.
  • Design and execute in vivo studies to evaluate efficacy of therapeutic virus candidates in cancer disease models.
  • Document, analyze, interpret and present results within a multi-disciplinary team environment.
  • Work closely with the research group, CRO’s and external collaborators.

Candidate should have a Ph.D. in Immunology/Oncology or related field.

  • Deep knowledge/expertise in immunology/immune oncology field.
  • Extensive experience performing xenograft and syngeneic or gene-edited mouse models of cancer is required.
  • Experience developing and executing cell-based assays.
  • Expertise in development of in vitro/in vivo/ex vivo assays to assess immune function.
  • Flow cytometry experience required.
  • Molecular biology experience is strongly preferred.
  • Excellent written and oral communication, organizational skills and time management.
  • Ability to work independently as well as collaboratively.
  • Adaptable to change and new challenges.
Application Instructions:

Applicants should send curriculum vitae, statement of research interests and experience, and contact information for three references to:

Michael Lyman, PhD